Literature DB >> 18271017

Use of mesenchymal stem cells to enhance bone formation around revision hip replacements.

Michelle Korda1, Gordon Blunn, Allen Goodship, Jia Hua.   

Abstract

Tissue engineering approaches to regenerate bone stock in revision total hip replacements could enhance the longevity of the implant and benefit the quality of the patient's life. This study investigated the impaction of allograft with mesenchymal stem cells in an ovine hip hemiarthroplasty model. In total, 10 sheep were divided into two groups with 5 sheep in each group. The groups were: 1) mesenchymal stem cells mixed with allograft; 2) allograft only as a control. Ground reaction force was assessed for limb function and showed that there was no significant difference in the recovery for animals in different groups. The amount of bone regenerated around the hip replacement was assessed using un-decalcified histology. The results showed that the stem cell group generated significantly more new bone at the implant-allograft interface and within the graft than the control group. The results from this study indicate that the use of stem cells on an allograft scaffold increases bone formation indicating that the use of stem cells for revision hip arthroplasty may be beneficial for patients undergoing revision surgery where the bone stock is compromised. (c) 2008 Orthopaedic Research Society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18271017     DOI: 10.1002/jor.20598

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  9 in total

1.  Shed blood-derived cells from total hip arthroplasty have osteoinductive potential: a pilot study.

Authors:  Tomokazu Yoshida; Masakazu Ishikawa; Yuji Yasunaga; Takuma Yamasaki; Mitsuo Ochi
Journal:  Clin Orthop Relat Res       Date:  2010-06-24       Impact factor: 4.176

Review 2.  Mesenchymal stem cells in the aseptic loosening of total joint replacements.

Authors:  Jukka Pajarinen; Tzu-Hua Lin; Akira Nabeshima; Eemeli Jämsen; Laura Lu; Karthik Nathan; Zhenyu Yao; Stuart B Goodman
Journal:  J Biomed Mater Res A       Date:  2017-02-01       Impact factor: 4.396

Review 3.  Recommendations and considerations for the use of biologics in orthopedic surgery.

Authors:  Stefan Zwingenberger; Christophe Nich; Roberto D Valladares; Zhenyu Yao; Maik Stiehler; Stuart B Goodman
Journal:  BioDrugs       Date:  2012-08-01       Impact factor: 5.807

4.  Stem cell engineered bone with calcium-phosphate coated porous titanium scaffold or silicon hydroxyapatite granules for revision total joint arthroplasty.

Authors:  Elena García-Gareta; Jia Hua; Faizal Rayan; Gordon W Blunn
Journal:  J Mater Sci Mater Med       Date:  2014-02-12       Impact factor: 3.896

5.  A tissue engineering strategy for the treatment of avascular necrosis of the femoral head.

Authors:  A Aarvold; J O Smith; E R Tayton; A M H Jones; J I Dawson; S Lanham; A Briscoe; D G Dunlop; R O C Oreffo
Journal:  Surgeon       Date:  2013-03-27       Impact factor: 2.392

Review 6.  Targeting regulation of stem cell exosomes: Exploring novel strategies for aseptic loosening of joint prosthesis.

Authors:  Tian-Liang Ma; Jing-Xian Chen; Zhuo-Ran Ke; Peng Zhu; Yi-He Hu; Jie Xie
Journal:  Front Bioeng Biotechnol       Date:  2022-08-10

7.  [Establishment of artificial joint aseptic loosening mouse model by cobalt-chromium particles stimulation].

Authors:  Shengyuan Jiang; Dan Li; Jianhao Jiang; Shangyou Yang; Shuye Yang
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2020-05-15

8.  The effect of temperature on the viability of human mesenchymal stem cells.

Authors:  Yannis Reissis; Elena García-Gareta; Michelle Korda; Gordon W Blunn; Jia Hua
Journal:  Stem Cell Res Ther       Date:  2013       Impact factor: 6.832

9.  Lower Limb Loading during Gait in Patients Long Period after Total Hip Arthroplasty Revision.

Authors:  Eliska Kubonova; Zdenek Svoboda; Miroslav Janura; Jiri Gallo; Sarka Duskova
Journal:  Biomed Res Int       Date:  2016-08-04       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.